Genitope is a drug development company in arrested development. It had hoped to find new ways to fight cancer with old weapons, but now it is just hoping to find a future. The company was researching immunotherapy treatments for cancer, using the body's own immune system to fight tumors. Genitope's leading drug candidate, MyVax, was a patient-specific immunotherapy that would specify the genetic makeup of the tumor, activate the patient's immune system to attack it, and cause no damage to cells other than the tumor. However, the drug did not do well in early clinical trials, and when the FDA requested additional trials for further review, Genitope chose to scrap the whole program.

Cellectis SA company develops technologies involving the research and development of rational genome engineering (making changes in the genetics of a cell or organism). The company's research is primarily based on the Meganucleasus, a natural classification of DNA that isolates unique breaks at key locations within living cells. Its patented Meganuclease Recombination Systems technology helps to initiate the rational genome engineering process, which in turn can help treat diseases and augment genetic codes.

New Leaf Brands, Inc. engages in the development, marketing, and distribution of ready-to-drink (RTD) beverages. Products The company’s New Leaf brand is a natural tea sweetened with organic cane sugar and specifically formulated to address the market for a healthy but appealing beverage. New Leaf is available in 13 flavors, integrating blue teas, green teas, black teas, and white teas. New Leaf products consist of Blue Teas, such as Diet Blue Tea with Lemon, Diet Blue Tea with Peach, Blue Tea with Lemon, Blue Tea with Peach, and Blue Tea with Raspberry; Green Teas, such as Green Tea with Plum, Green Tea with Ginseng, and Green Tea with Mango; White Teas, such as White Tea with Ginseng & Honey, White Tea with Honey Dew Melon, White Tea with Strawberry, and White Tea with Tangerine; and Black Tea: Mint & Lime International Sales The company sells its New Leaf brands in Canada and the Carribean. Customers New Leaf Tea is marketed to distributors, such as natural food, gourmet food, and mainstream distributors. The company’s major distributor is Manhattan Beer. Competition The company competes with soft drink companies, such as Coca Cola, Pepsi, and Cadbury Schweppes. In addition, it competes with beverage companies, including Arizona, Snapple, Lipton Brisk, Sobe, Vitamin Water, Fuze, Nestea, Tazo, Honest Tea, and Sweet Leaf Tea. Dispositions On October 9, 2009, the company completed the sale of its nutraceutical business, Nutritional Specialties, Inc. History The company was incorporated in 1986. It was formerly known as Baywood International, Inc. and changed its name to New Leaf Brands, Inc. on October 19, 2009.

Micromet, Inc. (Micromet) is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. Four of the Company's antibodies are in clinical trials, while the remainder of its product pipeline is in pre-clinical development. The Company’s BiTE antibody blinatumomab, known as MT103, is being evaluated in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase I clinical trial for the treatment of patients with non-Hodgkin’s lymphoma (NHL). A second BiTE antibody, MT110, is being tested in a phase I clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule (EpCAM), which is over-expressed in many solid tumors.

Gentronix is a biotechnology company that provides pharmaceutical makers with drug development products and monitoring services. Gentronix's products and services are geared toward helping drug discovery scientists speed up pre-clinical research and development. The company's main product, Greenscreen, uses cellular biosensor technology to test potential pharmaceutical compounds for genotoxicity (DNA damage) and cytotoxicity (general cellular damage). The company was founded in 1999 as part of the University of Manchester Institute of Science and Technology's Biomolecular Sciences and Instrumentation & Analytical Science departments.

Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California. Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006.

Peregrine Pharmaceuticals, Inc. company was founded in 1981 and is based in Tustin, California. Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and manufacture of monoclonal antibodies for the treatment of cancer and viral infections. The company develops clinical programs with its novel compounds bavituximab and Cotara, which are the clinical candidates under its anti-phosphatidylserine therapeutics and tumor necrosis therapy platforms. Its pipeline products comprise Bavituximab Plus Docetaxel, and Bavituximab plus carboplatin and paclitaxel, which are Phase II clinical trial products for treating advanced breast cancer patients; and Bavituximab plus carboplatin and paclitaxel, a Phase II clinical trial product for the treatment of non-small cell lung cancer, as well as Bavituximab, which is in Phase I monotherapy repeat dose safety study for treating solid tumor cancers, and in Phase Ib repeat dose safety study for the treatment of chronic hepatitis C virus infection co-infected with HIV. In addition, its pipeline products include Cotara, a product in Phase II, as well as a dosimetry and dose confirmation study for the treatment of glioblastoma multiforme, an aggressive form of brain cancer. Further, Peregrine, through its wholly owned subsidiary, Avid Bioservices, Inc., provides contract manufacturing services for biotechnology and biopharmaceutical companies, from pre-clinical drug supplies up through commercial-scale drug manufacture. Further, it provides services in support of Peregrine's product pipeline, including manufacture and scale-up of pre-clinical and clinical drug supplies.

Chimerix, Inc. company was founded in 2002 and is headquartered in Durham, North Carolina. Chimerix has developed technology to make molecules with therapeutic potential into oral drugs. Its lipid conjugate technology can modify drug compounds to mimic a particular lipid metabolite that is absorbed by the small intestine, thus protecting the compounds from being broken down in the stomach. Chimerix is using its technology to develop lead drug candidate CMX001 to fight smallpox infections or bad reactions to smallpox vaccinations. The development-stage firm is also targeting drug-resistant HIV and hepatitis.

Sino Biopharmaceutical manufactures medicines that combat cardio-cerebral diseases and hepatitis. Incorporated in 2000, Sino markets its products throughout China in the form of volume injections, PVC-free soft bags for intravenous injections, capsules, tablets, powdered medicines, and granulated medicines. It is additionally researching and developing new medicines in the realms of oncology, analgesic, and respiratory treatment. Sino primarily operates through four main subsidiaries: Beijing Tide Pharmaceutical, Jiangsu Chia Tai Tianqing Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, and Beijing Chia Tai Green Continent Pharmaceutical.

Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France. Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The company's Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The company's products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.